| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;43:603.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
From the Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Correspondence to Dr Koichi Hayashi, Department of Internal Medicine School of Medicine, Keio University, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan. E-mail khayashi{at}sc.itc.keio.ac.jp
Although the angiotensin-converting enzyme (ACE) inhibitor-induced bradykinin enhances nitric oxide (NO) release, bradykinin may also stimulate the production of an additional vasodilator, endothelium-derived hyperpolarizing factor (EDHF). This study examined the role of EDHF in mediating the NO-independent action of ACE inhibitors in canine renal microcirculation in vivo. We used intravital CCD camera videomicroscopy that allowed direct visualization of renal microcirculation in superficial and juxtamedullary nephrons in an in vivo, in situ, and relatively intact setting. In the presence of E4177 (an angiotensin receptor blocker), cilazaprilat (30 µg/kg) had no effect on diameter of superficial afferent arterioles (Aff), but it increased renal contents of bradykinin and nitrate plus nitrite, and it elicited dilation of juxtamedullary Aff (from 24.0±0.2 to 28.2±0.8 µm), juxtamedullary efferent arterioles (Eff) (from 24.2±0.2 to 28.0±0.8 µm), and superficial Eff (from 18.2±0.2 to 19.7±0.2 µm). These changes in diameters were prevented by N
-adamantaneacetyl-D-Arg-[Hyp3,Thi5,8,D-Phe7]bradykinin, a bradykinin receptor antagonist. The pretreatment with nitro-L-arginine methylester (L-NAME) plus E4177 eliminated the dilator response of juxtamedullary/superficial Eff and the increase in renal nitrate plus nitrite levels induced by cilazaprilat. In contrast, in the presence of E4177+L-NAME, cilazaprilat still caused 8%±3% dilation of juxtamedullary Aff, which was completely eliminated by proadifen, a cytochrome-P450 and KCa channel blocker. Collectively, the ACE inhibitor exerts multiple vasodilator mechanisms, including the inhibition of angiotensin II formation; blockade of angiotensin II activity appears to be a dominant mechanism in superficial Aff, whereas the bradykinin-induced NO acts on superficial Eff and juxtamedullary Aff/Eff. Furthermore, a putative EDHF is an additional mechanism for the ACE inhibitor-induced vasodilation of juxtamedullary Aff in vivo.
Key Words: angiotensin-converting enzyme bradykinin endothelium-derived factors arterioles nitric oxide
This article has been cited by other articles:
![]() |
G. A. Eppel, D. L. Jacono, M. Shirai, K. Umetani, R. G. Evans, and J. T. Pearson Contrast angiography of the rat renal microcirculation in vivo using synchrotron radiation Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1023 - F1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Fitzgerald, H. Bashari, J. A. Cox, H. C. Parkington, and R. G. Evans Contributions of endothelium-derived relaxing factors to control of hindlimb blood flow in the mouse in vivo Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1072 - H1082. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Salom, B. Arregui, L. F. Carbonell, F. Ruiz, J. L. Gonzalez-Mora, and F. J. Fenoy Renal ischemia induces an increase in nitric oxide levels from tissue stores Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2005; 289(5): R1459 - R1466. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Imig ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement Hypertension, March 1, 2004; 43(3): 533 - 535. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |